Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
magrolimab + rituximab + gemcitabine + oxaliplatin
- Development stage
- Unknown
- Lead developer
- Gilead Sciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination therapy of four drugs: **magrolimab** (a humanized monoclonal antibody against CD47), **rituximab** (an anti-CD20 monoclonal antibody), **gemcitabine** (a nucleoside analog chemotherapy agent), and **oxaliplatin** (a platinum-based chemotherapeutic). This regimen, known as **magrolimab + R-GemOx**, is under investigation primarily for relapsed/refractory B-cell non-Hodgkin’s lymphoma, including diffuse large B-cell lymphoma (DLBCL). Magrolimab blocks the CD47 "don't eat me" signal, promoting tumor cell phagocytosis by macrophages. Rituximab targets CD20 on B cells, inducing antibody-dependent cellular cytotoxicity and phagocytosis. Gemcitabine suppresses DNA synthesis, while oxaliplatin induces DNA cross-linking and apoptosis. Together, these agents aim to synergistically enhance antitumor efficacy by both immunomodulatory and cytotoxic mechanisms[4][5][6].
- Other names
- magrolimab + R-GemOx
02
Targets
Beyond the preview
Go deeper on magrolimab + rituximab + gemcitabine + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on magrolimab + rituximab + gemcitabine + oxaliplatin.